Granules India Limited · NSE:GRANULES
Granules India — Q4 FY19 Earnings Presentation
23 slides from Granules India's earnings presentation, May 9, 2019
Slide 1: Cover letter to stock exchanges
(Cy? GRANULES REGISTERED OFFICE GRANULES INDIA LTD., 2nd Floor, 3rd Block, My Home Hub, Madhapur, Hyderabad - 500 081, Telangana, INDIA. ‘ ' ' Tel: +91 40 30660000 Fax‘ +91 40 23115145 mai|@ granules:ndla.com, w WW granmesm dia.com , , , . CIN: L24110T61991PLC012471 Dated May 09I 2019 To, National S
Slide 2: Investor Presentation Q4 FY19
Investor Presentation Q4 FY19
Slide 3: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 4: Q4 FY19 Updates
G GRANULES Q4 FY19 Updates
Slide 5: Q4 Financial Performance Highlights
Q4 Financial Performance Highlights S A L E S F R O M O P E R AT I O N S EBITDA PAT Rs 613 Crs Rs 99 Crs Rs 64 Crs 22% over Q4FY18 87% over Q4FY18 223% over Q4FY18 Vertical wise – Q4FY19 Geography wise – Q4FY19 Production Details – Q4FY19 5,577 4% 8% 36% 15% 47% 3,353 54% 2,957 19% 17% North America
Slide 6: About Granules
G GRANULES About Granules
Slide 7: Granules at a Glance
Granules at a Glance Building Blocks Installed Capacity Regulatory Approvals Business Divisions Global Reach Regulatory Compliance 34,560 TPA of API USFDA, EDQM, EU Core Business 60+ countries Operational Efficiency 285 KL GMP, COFEPRIS, WHO US Generics 250+ customers 4,800 TPA (
Slide 8: Group Structure and Manufacturing Presence
Group Structure and Manufacturing Presence Incorporated in 1991, this is the only listed entity in the group, with 4 operational plants located in Hyderabad Granules India (Jeedimetla, Bonthapally and Gagillapur) and 1 in Vizag Pharma City 1 Granules USA Inc. 100% subsidiary, for front-end marketing
Slide 9: Business Structure – Granules India
Business Structure – Granules India Focus on core products including Auxiliary growth engine to secure the Paracetamol, Metformin HCl, Ibuprofen, future while strengthening the core Guaifenesin and Methocarbamol. Added business Cetrizine and Fexofenadine to the portfolio Growth avenue for diff
Slide 10: Core Business
Core Business Overview Drivers Value Enablers Present across the entire pharmaceutical One of the World’s largest PFI and single site FD facility manufacturing value chain from API to API capacity 34,560 MT, PFI 24,400 TPA & Finished Finished Dosages. Dosages 18 billion Scale DMFs, Dossiers,
Slide 11: Emerging Business: Multi APIs / Onco
Emerging Business: Multi APIs / Onco Overview Drivers Value Enablers Addition of USFDA approved multiproduct manufacturing site enabling scale-up and Multiproduct facility with an installed capacity of 285KL manufacturing of niche APIs through in- Integrated API to FD facility for Oncology hou
Slide 12: US Generics
US Generics Overview Drivers Value Enablers Fully integrated infrastructure from R&D, “Niche products,” hidden opportunities with different manufacturing to marketing enabling layers of complexities “Make in America” Differentiated dosage forms; limited competition Portfolio Complex generics
Slide 13: JVs – Granules Omnichem & Granules Biocause
JVs – Granules Omichem & Granules Biocause Granules Omnichem Overview Drivers Value Enablers 250 25% 19.1% Granules Biocause, a venture with China High margin opportunity in 200 20% 15.6% based Hubei Biocause operational since CRAMS with manufacturing for 2007. Objective is to enable core innova
Slide 14: Core Management Team
Core Management Team Mr. Krishna Prasad Chigurupati Mr. Prasad is the Founder of Granules and has three decades of experience in the pharmaceutical industry. In 1984, he set up a Paracetamol manufacturing facility, focused on capital and process efficiency. Pharmaceutical Formulations Intermediates
Slide 15: Operational Performance Matrics
Operational Performance Matrics 14 14
Slide 16: Core – 5 Molecule driven business
Core – 5 Molecule driven business 431 1,891 3 Year CAGR 223 1,193 44 17% Y-o-Y Growth in FY’19 30% Total Contribution Addition during Addition during Addition during Total Contribution in year - 2016 2017 2018 2019 in year - 2019 # Core 5 molecule include Paracetamol; Metformin; Ibuprofen; Guaifenes
Slide 17: Consolidated Operational Metrics
Consolidated Operational Metrics Product Vertical wise Revenue Revenue share in FY’19 1,076 FD 675 API PFI 462 543 36% 387 FD API 387 343 418 47% 820 533 550 598 PFI 17% 2016 2017 2018 2019 110 Geography wise Revenue contribution 198 403 89 197 77 67 457 147 166 408 309 355 337 292 265 1,111 539 601
Slide 18: Financial Performance Matrics
Financial Performance Matrics 17 17
Slide 19: Consolidated Financial Overview – Trends
Consolidated Financial Overview – Trends Revenue EBITDA PAT PAT Margin EBITDA Margin 2,500 21.4% 35.0% 20.4% 17.8% 30.0% 2,000 17.0% 25.0% 1,500 20.0% 2,279 15.0% 1,000 11.4% 10.3% 8.9% 1,692 1,383 1,435 7.8% 10.0% 500 236 5.0% 123 165 133 411 282 309 289 - 0.0% FY'16 FY'17 FY'18 FY'19 Balance Sheet
Slide 20: Balance Sheet Highlights
Balance Sheet Highlights Net Debt to EBITDA (Times) ROCE Asset Turnover (Times) 3.0 19.7% 1.7 2.2 13.9% 2.0 11.7% 1.6 1.5 Mar-17 Mar-18 Mar-19 Mar-17 Mar-18 Mar-19 Mar-17 Mar-18 Mar-19 Net Debt to Equity (Times) ROE Cash to Cash Cycle (In Days) 0.7 21.0% 120 120 0.7 16.7% 12.0% 0.6 110 Mar-17 Mar-18
Slide 21: Way Forward
G GRANULES Way Forward
Slide 22: Way Forward
Way Forward Building Profitable Growth Steady Returns Blocks in Place through Execution to the Stakeholders Integrated platform in place that can Expanding portfolio range with Financial discipline to a key focus address the entire value chain from addition of differentiated and intermediates
Slide 23: For further information, please contact
For further information, please contact: Company Investor Relations contact Sumanta Bajpayee Head - Corporate Finance & Investor Relations 040-30663572 sumanta.bajpayee@granulesindia.com 532482 GRANULES GRAN:IN GRAN:NS 22